newsfilter
← Latest News
Earnings Call Transcripts·

Ascend Wellness Holdings Q3 2026 Earnings Conference Call - Ascend Wellness Holdings, Inc.

AAWH

  • Explicit Guidance:

    • Q4 2026 Revenue: Top-line growth expected at approximately 1% to 2%, driven by new store ramp-up and M&A pipeline, partially offset by seasonal discounting and price compression.
    • Q4 2026 Margins: Adjusted EBITDA margin expected to remain similar to Q3 levels (approx. 23.9%).
    • Full Year 2026 CapEx: Total expected at approximately $20 million (with $15.7 million already deployed); remaining capital allocated to new store openings and maintenance for cultivation/manufacturing facilities.
    • 2027 Outlook: Growth in retail sales identified as a "meaningful source" of EBITDA and cash flow growth into 2027.

  • Business-Segment Outlook:

    • Retail Expansion: Continued store openings planned beyond the 60-store target, including 2 additional partner store opportunities in New Jersey expected to open early next year (increasing NJ footprint to 9 locations).
    • Massachusetts Expansion: Two new dispensaries in Worcester and Shrewsbury operating under consulting agreements pending regulatory approval for acquisition closing; expected vertical integration will extend medical licenses to all MA stores and the Nathel cultivation facility.
    • Product Innovation: Launch of Ozone Signature premium flower lineup in core markets; new Honor Roll formats (premium glass tip, 10-pack, 2-pack) expected later in the quarter; F&Tabs edibles launched in October in NJ, MA, and IL.
    • Brand Performance: Targeting #1 status in every core market; Ozone holding #3 in dollar sales across core markets; Simply Herb Vapes ranking #6 in NJ; High Wired ranking #1 infused flower in NJ.
    • Wholesale Strategy: Intentional shift of wholesale volume to retail channel to control pricing and margins; wholesale decline viewed as structural shift rather than volume loss, with expectations to sell only high-velocity products.

  • Market and Competitive Outlook:

    • Share Gains: Expectation that share of demand from the unregulated intoxicating hemp market will move into the regulated market following the federal deadline (December 11, 2026).
    • Competitive Positioning: Anticipation of a "900-pound gorilla" status in core markets driven by verticality and operating leverage; focus on maintaining price competitiveness for wholesale partners while prioritizing high-margin retail.
    • Pricing Dynamics: Continued price compression anticipated in Q4 due to end-of-year wholesale promotional pressure and seasonal discounting.

  • Macro / Industry Outlook:

    • Regulatory (Federal): Monitoring DEA hearing outcome on rescheduling (currently with judge for recommendation); federal hemp loophole deadline moved to December 11, 2026, with potential for further shifts.
    • Regulatory (State): Massachusetts voters rejected adult-use repeal (reinforcing legalization durability); Ohio implemented bans ahead of federal deadline, expected to drive near-term demand shifts.
    • Capital Markets: Shareholders approved reverse stock split (timing to be determined); board intends to utilize split for an uplisting to a major U.S. exchange when permissible.
    • Economic/Interest Rates: Interest payments noted as a recurring pressure on Q1 and Q3 cash flow; management emphasizes cost management and working capital discipline as key mitigants.

  • Strategic Initiatives:

    • International Expansion: First international foray via licensing agreement with Atlantic Cultivation (Canada); two flagship brands (High Wired Infused Pre-Rolls, Ozone Liquid Diamond Vapes) expected on shelves in Canada starting Q1 2027.
    • M&A Strategy: Engaging in dozens of active conversations; $11 million mortgage financing secured to fund non-dilutive capital for densification and acquisitions.
    • Operational Efficiency: Continued focus on yield improvement (21% increase since Q1 2025) and unit labor productivity; capital allocation remains disciplined with a high hurdle rate (targeting >30% return on invested capital).
    • Payment Technology: Rolling out contactless "tap-to-pay" across network; "Ascend Pay" adoption noted at >11% of transactions.

  • Risks and Headwinds to Outlook:

    • Regulatory Uncertainty: Timing and outcome of federal rescheduling remain uncertain; potential delays in state regulatory approvals (e.g., NJ partner stores).
    • Market Headwinds: Ongoing price compression and potential for increased promotional pressure in Q4 could suppress top-line growth rates.
    • Execution Risks: M&A execution varies in timing; store openings (especially new doors) typically take longer than a quarter to ramp to full contribution.
    • External Factors: Potential shifts in federal hemp loopholes or state-level bans affecting timing of demand reallocation.

  • Management Tone on the Future:

    • Confidence: High confidence in long-term durability of adult-use cannabis and the effectiveness of the "customer-first" retail model; optimistic about M&A pipeline and "dipping the toe" into international markets.
    • Strategic Focus: Shift from pure SKU maximization to scaling house brands and controlling the retail channel to drive margins; "relentless" pursuit of facility scale and efficiency.
    • Guidance vs. Prior: Guidance is conservative regarding Q4 pricing but emphasizes strong momentum from store ramp-up and operating leverage as key drivers for 2027.

  • Miscellaneous:

    • Financial Health: Ended Q3 with $63.6 million in cash; positive operating cash flow generated despite biannual interest payments ($19.1 million); $11 million in non-dilutive capital secured via mortgage loans (maturing Oct 2031).
    • Customer Metrics: Loyalty members account for 86% of transactions; average Google rating held at 4.66; new traffic up 19% network-wide.